Details of the Drug Combination

General Information of Drug Combination (ID: DCS9IXJ)

• Drug Combination Name: Mizoribine + RG6046
• Indication: Lymphoid neoplasm; Status: Investigative [1]
• Component Drugs:
  Mizoribine (DMW6F0S): Small molecular drug
  RG6046 (DMGYWIK): N.A.
• High-throughput Screening Result:
  Testing Cell Line: Mak
  Zero Interaction Potency (ZIP) Score: 3.114
  Bliss Independence Score: 1.716
  Loewe Additivity Score: 1.386
  LHighest Single Agent (HSA) Score: 7.418

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Mizoribine

Disease Entry	ICD 11	Status	REF
Transplant rejection	NE84	Approved	[2]

Mizoribine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)	TTL7C8Q	IMDH1_HUMAN	Inhibitor	[4]

Mizoribine Interacts with 1 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Increases Expression	[5]

Indication(s) of RG6046

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Investigative	[3]

RG6046 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Estrogen receptor (ESR)	TTZAYWL	ESR1_HUMAN	Modulator	[3]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001 May;90(5):625-37.
• [5] Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.